{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:14:29Z","timestamp":1789917269153,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1053\/sarh.2002.34606","type":"journal-article","created":{"date-parts":[[2003,1,14]],"date-time":"2003-01-14T13:11:29Z","timestamp":1042549889000},"page":"157-162","source":"Crossref","is-referenced-by-count":34,"title":["Interferon-induced Raynaud's syndrome"],"prefix":"10.1053","volume":"32","author":[{"given":"Daniel","family":"Schapira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham Menahem","family":"Nahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuhad","family":"Hadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/sarh.2002.34606_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","article-title":"Clinical toxicity of the interferons","volume":"10","author":"Vial","year":"1994","journal-title":"Drug Safety"},{"key":"10.1053\/sarh.2002.34606_bib2","first-page":"945","article-title":"Raynaud's phenomenon and cryoglobulinemia associated with the use of recombinant human alpha- interferon","volume":"I","author":"Roy","year":"1988","journal-title":"Lancet"},{"key":"10.1053\/sarh.2002.34606_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2796.1994.tb01111.x","article-title":"Raynaud's phenomenon associated with interferon therapy","volume":"235","author":"Arslan","year":"1994","journal-title":"J Internal Med"},{"key":"10.1053\/sarh.2002.34606_bib4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(94)92386-8","article-title":"Transient blurred vision after interferon for chronic hepatitis C","volume":"344","author":"Ene","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/sarh.2002.34606_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/112067219500500413","article-title":"Bilateral transient visual obscurations with headaches during alpha-II interferon therapy: a case report","volume":"5","author":"Detry-Morel","year":"1995","journal-title":"Eur J Ophtalmol"},{"key":"10.1053\/sarh.2002.34606_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2133.1996.tb01521.x","article-title":"Raynaud's phenomenon and digital necrosis induced by interferon-alpha","volume":"135","author":"Bachmeyer","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1053\/sarh.2002.34606_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/000331979604700210","article-title":"Severe Raynaud's syndrome associated with interferon therapy. a case history","volume":"2","author":"Creutzig","year":"1996","journal-title":"Angiology"},{"key":"10.1053\/sarh.2002.34606_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/mvre.1996.0066","article-title":"Microangiopathy in patients with chronic myelogenous leukemia treated with interferon","volume":"52","author":"Creutzig","year":"1996","journal-title":"Microvasc Res"},{"key":"10.1053\/sarh.2002.34606_bib9","first-page":"654","article-title":"A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels","volume":"23","author":"Polisson","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2002.34606_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0248-8663(97)84017-9","article-title":"Syndrome de Raynaud compliqu\u00e9 de gangr\u00e8ne digitale au cours d'un traitement par l'interferon alpha","volume":"18","author":"Liozon","year":"1997","journal-title":"Rev M\u00e9d Interne"},{"key":"10.1053\/sarh.2002.34606_bib11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(05)60005-0","article-title":"Severe Raynaud's phenomenon associated with interpheron-\u03b2 treatment for multiple sclerosis","volume":"352","author":"Linden","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/sarh.2002.34606_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000040874","article-title":"Interferon-induced vasospasm in chronic myeloid leukemia","volume":"100","author":"Zeidman","year":"1998","journal-title":"Acta Hematol"},{"key":"10.1053\/sarh.2002.34606_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1590\/S0004-282X2000000300025","article-title":"Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report","volume":"58","author":"Cruz","year":"2000","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1053\/sarh.2002.34606_bib14","first-page":"424","article-title":"Ph\u00e9nom\u00e8ne de Raynaud s\u00e9v\u00e8re associ\u00e9 \u00e0 un traitement par interf\u00e9ron beta-1a et flux\u00e9tine","volume":"151","author":"De Broucker","year":"2000","journal-title":"Ann M\u00e9d Interne"},{"key":"10.1053\/sarh.2002.34606_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1026586629166","article-title":"Interferon-\u03b1 induced Raynaud's syndrome","volume":"11","author":"Kruit","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/sarh.2002.34606_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJM199205283262209","article-title":"Interferons-expanding therapeutic roles","volume":"326","author":"Border","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/sarh.2002.34606_bib17","first-page":"1182","article-title":"Antimicrobial agents","author":"Gordon Douglas","year":"1992"},{"key":"10.1053\/sarh.2002.34606_bib18","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5","article-title":"Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy","volume":"65","author":"Conlon","year":"1990","journal-title":"Cancer"},{"key":"10.1053\/sarh.2002.34606_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0090-1229(92)90250-R","article-title":"Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders","volume":"65","author":"Wandl","year":"1992","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1053\/sarh.2002.34606_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1378\/chest.99.3.557","article-title":"Cardiotoxicity of interferon","volume":"99","author":"Sonneblick","year":"1991","journal-title":"Chest"},{"key":"10.1053\/sarh.2002.34606_bib21","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archopht.1995.01100080093034","article-title":"Anterior ischemic optic neuropathy secondary to interferon alpha","volume":"113","author":"Purvin","year":"1995","journal-title":"Arch Ophtalmol"},{"key":"10.1053\/sarh.2002.34606_bib22","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1177\/000331979504601210","article-title":"Interferon-induced coronary vasospasm","volume":"46","author":"Tanaka","year":"1995","journal-title":"Angiology"},{"key":"10.1053\/sarh.2002.34606_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/BF02355061","article-title":"Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C","volume":"31","author":"Tada","year":"1996","journal-title":"J Gastroenterol"},{"key":"10.1053\/sarh.2002.34606_bib24","first-page":"538","article-title":"Adhesion and penetration properties of human lymphocytes acting on allogenic endothelial cells","volume":"81","author":"Blaheta","year":"1994","journal-title":"Immunology"},{"key":"10.1053\/sarh.2002.34606_bib25","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI116486","article-title":"Interferon \u03b1 and interleukin 2 synergistically enhance basic fibroblast growth factor and induce release promoting endothelial cell growth","volume":"91","author":"Cozzolino","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1053\/sarh.2002.34606_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-4362.1991.tb04230.x","article-title":"Cutaneous local necrosis following interferon injection","volume":"30","author":"Cnudde","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1053\/sarh.2002.34606_bib27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmune effect of interferon therapy for malignant carcinoid tumors","volume":"115","author":"R\u00f6nnbloom","year":"1991","journal-title":"Ann Int Med"},{"key":"10.1053\/sarh.2002.34606_bib28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archopht.1993.01090030068041","article-title":"Interferon-associated retinopathy","volume":"111","author":"Guyer","year":"1993","journal-title":"Arch Ophtalmol"},{"key":"10.1053\/sarh.2002.34606_bib29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0090-1229(87)90146-2","article-title":"A unifying model of the immunoregulatory role of the interferon system: Can interferon produce disease in humans?","volume":"43","author":"Scurkovich","year":"1987","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1053\/sarh.2002.34606_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(87)93034-0","article-title":"Clinical significance of anti-IFN-\u03b1 antibody titres during interferon therapy","volume":"ii","author":"Von Wussow","year":"1987","journal-title":"Lancet"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017202000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017202000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:42:07Z","timestamp":1583973727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017202000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S0049017202000732"],"URL":"https:\/\/doi.org\/10.1053\/sarh.2002.34606","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}